A5064039277- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- Pharmaceutical studies and practices
- Intramuscular injections and effects
- Treatment of Major Depression
- Pharmacological Effects and Toxicity Studies
- Bipolar Disorder and Treatment
- Animal Virus Infections Studies
- Advancements in Transdermal Drug Delivery
- Pharmaceutical Economics and Policy
- Long-Term Effects of COVID-19
- Schizophrenia research and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Head and Neck Cancer Studies
- Bacillus and Francisella bacterial research
- Pharmaceutical Practices and Patient Outcomes
- Dermatology and Skin Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Urinary Tract Infections Management
- Medication Adherence and Compliance
- Dermatological and COVID-19 studies
- PARP inhibition in cancer therapy
Mahidol University
2011-2024
Siriraj Hospital
2011-2024
The University of Queensland
2014
The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector vaccination is unclear.
Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector (ChAdOx1) have been widely used in resource-limited settings. However, the information on reactogenicity immunogenicity of these two vaccines same setting are limited.Healthy health care workers (HCWs) aged 18 years or older were randomly assigned to receive either doses CoronaVac at 4 weeks interval ChAdOx1 10 interval. Self-reported adverse events (AEs) collected for 7 days following each vaccination. Immunogenicity was...
We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) CoronaVac (Sinovac) in healthy adults, as well booster response to following regimens. Participants were randomized one seven groups that received two-dose homologous or combinations CoronaVac, BNT162b2, with 4 weeks interval. A total 210 participants enrolled, 30 each group. Median age was 38 (19-60) years, 108/210 (51.43%) female....
We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, risk development. PCR-confirmed SARS-CoV-2-infected patients were enrolled (2:1) within 10 days symptomatic onset into FPV control arms. The former received 1800 mg twice-daily (BID) on Day 1 800 BID 5-14 thereafter until negative detection, while the latter only supportive care. primary endpoint was time to improvement, defined by a National...
The study aimed to compare the immunogenicity and safety of fractional (half) third doses heterologous COVID-19 vaccines (AZD1222 or BNT162b2) full after two-dose CoronaVac when boosting three different extended intervals.
Triple negative breast cancer (TNBC) is a subtype characterized by absence of both hormonal receptors and human epithelial growth factor receptor 2 (HER2). TNBC accounts for 15-20% cancer. associated with more aggressive disease worse clinical outcome. Though the underlying mechanism currently unclear, heterogeneity characteristics in various population may relate to difference tumor mutational profile. There were studies on gene mutations ethnic groups but genome data Thai patients unknown....
Abstract The CoronaVac (Sinovac Biotech) and ChAdOx1(Oxford-AstraZeneca) are two widely used COVID-19 vaccines. We examined the immunogenicity of four booster vaccine: BBIBP-CorV (Sinopharm Biotech), ChAdOx1, 30μg-BNT162b2 15μg-BNT162b2 (Pfizer-BioNTech), in healthy adults who received a two-dose or ChAdOx1 8-12 weeks earlier. Among 352 participants (179 173 participants), 285 (81%) were female, median age was 39(IQR: 31-47) years. 98%(175/179) 99%(172/173) Coronavac remained seropositive at...
Intradermal vaccination using fractional dosages of the standard vaccine dose is one strategy to improve access COVID-19 immunization. We conducted a pilot study in healthy adults Thailand evaluate safety and immunogenicity intradermal administration doses ChAdOx1 (1/5th dosage) or BNT162b2 (1/6th individuals previously vaccinated (prime) with two-dose intramuscular CoronaVac, BNT162b2. Following an initial exploratory phase for each combination group (
A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone pioglitazone utilisation in Australia following timing these various health authority warnings such as Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) press releases or U.S. Food Drug (FDA) is unknown. This study investigated before after major drug authorities. We evaluated dispensing using Pharmaceutical Benefit Scheme (PBS) subsidised data for population from...
There is a limited supply of COVID-19 vaccines, with less than 20% eligible populations in low-income countries having received one dose. Intradermal delivery fractional dose vaccines way to improve global vaccine access, but no studies have reported data on intradermal primary series vaccination. We conducted pilot study examine the safety and immunogenicity three regimens - heterologous regimen CoronaVac ChAdOx1 (CoronaVac-ChAdOx1), homologous (ChAdOx1-ChAdOx1), BNT162b2...
Intradermal (ID) vaccination may alleviate COVID-19 vaccine shortages and hesitancy.Persons aged ≥65 years who were vaccinated with 2-dose ChAdOx1 12-24 weeks earlier randomized to receive a booster by either ID (20 µg mRNA-1273 or 10 BNT162b2) intramuscular (IM) (100 30 route. Anti-receptor-binding domain (RBD) immunoglobulin G (IgG), neutralizing antibody (NAb), interferon gamma (IFN-γ)-producing cells measured at 2-4 following vaccination.Of 210 participants enrolled, 70.5% female median...
This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous homologous COVID-19 vaccination schedules in pregnant Thai women. 18–45-year-old women with no history infection or a gestational age ≥12 weeks were randomized 1:1:1 into three two-dose primary series scheduled 4 apart: BNT162b2-BNT162b2 (Group 1), ChAdOx1-BNT162b2 2), CoronaVac-BNT162b2 3). Serum antibody responses, maternal cord blood levels at delivery, adverse events (AEs) following until...
Abstract The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector vaccination is unclear. We evaluated the safety and immunogenicity of different vaccines, (BBIBP-CorV), chimpanzee (ChAdOx1), mRNA (BNT162b2 at full (30 µg), half (15 µg) dose) in healthy adults who received 2-dose primary series either (CoronaVac) ChAdOx1 8-12 weeks earlier. Overall, adverse events for all vaccines were mild moderate. Two post-booster dose, neutralising antibody titres against Delta...
The pharmacokinetics of olanzapine are linear and doseproportional within the approved dosage range from 1 mg up to 20 mg.Olanzapine is well absorbed following oral administration in both fed fasted states .Food does not affect rate or extent absorption.Time peak concentration ranges 2-7 h [4,5].Olanzapine extensively distributed throughout body, binding primarily albumin (90%) α -acid glycoprotein (77%).Olanzapine eliminated (40%) dose by first pass metabolism.Direct glucuronidation CYP1A2...
Abstract Importance Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector (ChAdOx1) have been more available in resource-limited settings. However, the data comparing between these two vaccines same setting are limited. Objectives To determine adverse events (AEs) immunogenicity of CoronaVac ChAdOx1 health care workers (HCWs). Design This prospective study was conducted from February to July 2021. Setting A single center, university-based tertiary center Bangkok. Participants...
Abstract Intradermal vaccination using fractional dosage of the standard vaccine dose is one strategy to improve access COVID-19 immunization. We conducted a pilot study in healthy adults Thailand evaluate safety and immunogenicity intradermal administration ChAdOx1 (1/5 th dosage) or BNT162b2 (1/6 individuals previously vaccinated (prime) with two-dose intramuscular CoronaVac, BNT162b2. Following an initial exploratory phase for each combination group (N=10), total 135 participants (N=45...
To evaluate immunogenicity and safety of heterologous COVID-19 primary vaccination regimens CoronaVac with fractional standard BNT162b2 dosages in 5-11-year-old Thai children.This prospective, multicenter, double-blind, randomized control trial divided participants 1:1:1:1 to receive a second dose either (10-μg) or half-dose (5-μg) vaccines as follows: CoronaVac/10-μg-BNT162b2 (Group 1), CoronaVac/5-μg-BNT162b2 2), 10-μg-BNT162b2/10-μg-BNT162b2 3), 10-μg-BNT162b2/5-μg-BNT162b2 4). A subset...
Abstract We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary series vaccination schedules. Participants were randomized to one seven groups that received two-dose homologous BNT162b2 or combinations CoronaVac, ChAdOx1 BNT162b2, with 4 weeks interval. Of 210 participants, median age was 38 (19-60) years, 51% female. The as second dose induced highest virus-specific IgG response against ancestral strain [BNT162b2: geometric mean concentration (GMC) 2133-2249,...
Abstract Summary Half-dose AZD1222 or BNT162b2 boosters maintained immunogenicity and safety, were non-inferior to full doses. All doses elicited high best with extended post-CoronaVac primary-series intervals (120-180 days) high-transmissibility Omicron. Methods At 60-to-<90, 90-to-<120, 120-to-180 days (‘intervals’) primary-series, participants randomized full-dose half-dose BNT162b2, followed up at day-28, -60 -90. Vaccination-induced Ancestral, Delta Omicron BA.1 strains evaluated...
Geriatric populations are at an increased risk of severe presentations, hospitalization, and loss life from COVID-19. Few studies have explored vaccination regimens in adults >65 years old. Repeated booster is required for high-risk as COVID-19 vaccine efficacy short-lived. We compared the immunogenicity reactogenicity second intradermal (ID) with intramuscular (IM) older adults. This single-center, open-labeled, prospective, cohort study conducted Siriraj Hospital enrolled ≥65 old who...
Impact of frailty towards immunogenicity and reactogenicity BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population DESIGN: Prospective, randomized, open-labeled.